Gold prices rise from 2-wk low with focus on Russia-Ukraine, Jackson Hole
John Leite, the Chief Commercial Officer of Veracyte, Inc. (NASDAQ:VCYT), a $2.15 billion market cap diagnostics company with a GREAT financial health score according to InvestingPro, recently executed a sale of 2,809 shares of the company’s common stock. The transaction, which took place on June 4, 2025, was conducted under a pre-established Rule 10b5-1 trading plan adopted in December 2024. The shares were sold at a weighted average price of $27.2018, with sale prices ranging from $26.82 to $27.36, amounting to a total sale value of $76,409. This sale occurs as the stock has declined 31.87% year-to-date, with notably volatile price movements. Following this transaction, Leite holds 94,540 shares of Veracyte stock. For comprehensive insider trading analysis and 12 additional ProTips about VCYT, visit InvestingPro.
In other recent news, Veracyte, Inc. reported impressive financial results for the first quarter of 2025, surpassing analysts’ expectations. The company achieved earnings per share of $0.31, significantly higher than the anticipated $0.02, and revenue of $114.5 million, exceeding the forecasted $111.14 million. Needham analysts have adjusted their price target for Veracyte to $41.00 from $51.00, while maintaining a Buy rating, reflecting a broader contraction in peer multiples despite the company’s strong operational performance. Meanwhile, Scotiabank (TSX:BNS) reaffirmed its Sector Outperform rating with a $44.00 price target, citing Veracyte’s continued growth in test volumes for Decipher Prostate and Afirma. Veracyte’s management confirmed revenue guidance for 2025 and increased its adjusted EBITDA margin guidance, highlighting robust sales of its Decipher and Afirma tests. The company is also set to launch the Prosigna Breast Cancer assay as a laboratory-developed test in mid-2026, which analysts believe will benefit from Veracyte’s established clinical reputation. Additionally, Veracyte is progressing with its Decipher prostate metastatic launch, aiming for a broad release in June, which is expected to enhance its growth trajectory in the prostate cancer market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.